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Background: Intensive care unit (ICU) patients usually have abnormal biochemical and hematological laboratory
test results as a consequence of organ dysfunction and underlying disease. Thromboelastography (TEG®) is a
point-of-care laboratory analysis that gives an overview of several aspects of the coagulation process. In order to be
able to perform a clinical interpretation of abnormal TEG® results the expected values from non-bleeding ICU
patients should be known. The aim of this study is to report the normal variability observed in non-bleeding,
non-transfused ICU patients.
Methods: Adult ICU patients without bleeding in the last 24 hours, who had not received blood products within
the last 24 hours, with no hematological diseases and no anticoagulation therapeutic treatment were included.
Standard clinical chemistry tests, coagulation tests and TEG® were obtained. All results were reported in relation to
standard reference values. TEG® values were compared with routine coagulation measurement using Spearman
correlations.
Results: We observed that the normal variability observed in non-bleeding, non-transfused ICU patients in this
study included abnormally high TEG® values for maximum amplitude (MA) (73%). None of the patients showed MA
results corresponding to hypocoagulability. Other coagulation tests were also changed with elevated D-Dimer,
fibrinogen and APTT values, and a low ATIII value.
Conclusion: In unselected ICU patients without bleeding or known factors that influence coagulation, a TEG® value
of MA is often elevated suggesting hypercoagulability. This finding should be considered when interpreting TEG®
observations obtained in ICU patients.
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Intensive care unit (ICU) patients usually have abnormal
biochemical and hematological test results as a conse-
quence of organ dysfunction and underlying disease [1].
Coagulation abnormalities in the ICU setting can be
multifactorial and must be identified early in order to
start adequate treatment. In general, global coagulation
tests such as international normalized ratio (INR), acti-
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unless otherwise stated.and prothrombin time (PT) are used to monitor the
coagulation system. These tests have several limitations
as they are performed in plasma or serum, and do not
reflect the in vivo haemostatic process or the function of
the cell components in the coagulation system. New
point-of-care methods, such as rotational thomboelasto-
metry (ROTEM®) and thromboleastography (TEG®), have
increasingly been used in the last decade to assess the
haemostatic function. These tests have many advantages
compared to routine coagulation tests as they give an
overview of several aspects of the coagulation process,
from the initial thrombin formation to the clot lysis.
TEG® was developed by Hartert in 1948 and it measures
the viscoelastic changes that occur during coagulationtral. This is an Open Access article distributed under the terms of the Creative
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tation that reflects the initial fibrin-platelet interaction,
platelet aggregation, clot strength, rate of fibrin poly-
merization, and fibrinolysis [2]. TEG® is a well-established
tool for monitoring coagulation during and after liver
transplantation and cardiac surgery [3]. Several studies
show that the use of TEG®-based algorithms reduces
transfusion requirements in cardiac surgery [3,4].
The reference values for the TEG® are based on results
from healthy individuals and they might not be directly
applicable to all patients [5-7]. Previous studies have
investigated the TEG® results in ICU patients with sepsis,
but to our knowledge, there are no studies where TEG®
analysis has been performed in a general ICU patient
population without active bleeding or a recent blood
transfusion history [6,8].
In order to be able to perform a clinical interpretation
of abnormal TEG® results in the ICU one of the require-
ments is to establish the expected values from non-
bleeding ICU patients. Therefore, the aim of this study is
to report the normal variability observed in non-bleeding,
non-transfused ICU patients and to compare TEG® find-
ings with other coagulation tests.
Methods
Patients and setting
This study was performed at the 9-bed mixed case ICU
at St. Olav University Hospital, Trondheim, Norway, in
the period June 2012 to September 2013. In this period
it was decided to obtain conventional coagulation tests
and point of care coagulation test (TEG®) as part of rou-
tine care. Routinely an extended set of analyses including
coagulation tests is obtained from all patients in the unit
twice weekly (Monday and Thursday). As a part of a
quality assurance initiative test results in this period
were collected and analyzed retrospectively. Inclusion
criteria for the present analyses were ICU patients older
than 18 years with a length of stay more than 12 hours.
Patients were excluded by the following criteria: known
bleeding exceeding 300 ml the last 24 hours before sam-
pling, hemoglobin (Hgb) -variability of ≥ 2 g/dl within
6 hours prior to or 6 hours after the sample was taken,
any transfusion of blood products (red blood cells. fresh
frozen plasma. platelet concentrate or others) the last
24 hours before sampling, known bleeding disorders
(e.g. hemophilia or other factor deficiencies) or other
diseases expected to affect coagulation (e.g. hemato-
logical malignancies), and use of anticoagulants (ex-
cept enoxaparin ≤40 mg/day and/or acetylsalicylic
acid ≤300 mg/day).
Clinical variables
All data were collected from the patients’ hospital
records. Variables obtained included demographic data,primary diagnosis during the ICU-stay, Simplified Acute
Physiology Score II (SAPS II) [9], Sequential Organ Failure
Assessment (SOFA) score [10] (for the day of the TEG®-
sample) and all medications.Blood analyses
Arterial blood samples for the kaolin TEG®-analysis were
drawn from an arterial line into a tube containing 3.2%
sodium-citrate and were analyzed within 2 hours accord-
ing to the manufacturers recommendations [11] after
recalcification with 20 μl 0.2 M CaCl2. A total of five
TEG®-variables were recorded; reaction time (R), k-time
(K), maximum amplitude (MA), angle (α) and the calcu-
lated G-value. Briefly, R represents the time until initial
fibrin formation, K and α represent speed and kinetics of
clot formation, MA represents the maximal clot strength
and stability of the fibrin clot and G is calculated from
the MA providing a more sensitive parameter for changes
in clot strength [11].
Hemoglobin, white blood cell count, creatinine, biliru-
bin, sodium, potassium, ionized calcium, magnesium,
phosphate, albumin, C-reactive protein (CRP), platelet
count, INR, d-dimer, fibrinogen, antithrombin-III and
aPTT were obtained using the hospitals standard analyt-
ical methods. Due to practical concerns the blood sam-
ples for the TEG® were obtained two hours later than
the other tests.Analysis/statistics
IBM SPSS version 21 was used for all statistical analysis.
For biochemistry and TEG®-values. the median and
interquartile range were used for descriptive data. All
TEG®-values were also compared to the manufacturers
reference values [11], and categorized as below, within
or above these reference values.
Spearman correlations were performed for all TEG®-
variables according to age and gender. Correlation ana-
lysis was performed between time from sampling and
TEG®-parameters. We also analyzed possible correla-
tions between TEG®-parameters with other coagulation-
parameters, and clinical chemistry tests expected to
affect coagulation. This is a descriptive study and no
adjustments for multiple testing were performed. Given
the multiple statistical tests, we considered only p-
values < 0.01 significant in order to diminish risk of
type-I errors.Ethics
The Regional Committee for Medical and Health Re-
search Ethics Norwegian Central approved the study and
because samples were obtained for clinical routine use
waived the need for an informed consent.
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We included 82 patients (61% male, median age 61 years)
in the study. The most frequent diagnoses for ICU
admission were respiratory failure, infections, trauma
and non-traumatic CNS diseases (Table 1). The median
SAPS II score was 38 (IQR 29–49) and median total
SOFA score was 6 (IQR 4–8). An overview of the patients’
medications and results from the routine biochemistry
tests is shown in Table 1.
Median platelet count and INR were within normal
values. Median fibrinogen and D-dimer were higher than
reference values and median ATIII values were low com-
pared with normal values. The numbers of observations
below and above reference values are given in Table 2.
MA and G values were in 73% of the cases above the
manufacturer’s reference range (Table 2). For the rest of
the TEG®-parameters the results were within reference
values in most patients (Table 2).
There was no significant correlation between age or
gender with TEG® values. The median time from sam-
pling to analyses was 50 minutes (IQR: 33–82). There
were no significant correlations between time from sam-
pling to analysis and TEG® values.
Correlations for TEG®-variables with standard coagu-
lation tests and hemoglobin are shown in Table 3. We
observed strong correlations between MA and the platelet
count (r = 0.680, p > 0.001) and fibrinogen (r = 0.619,
p < 0.001). Hgb correlated negatively with MA (r = −0.379,
p < 0.001). G shoved the same pattern of correlations as
MA. K was correlated with APTT (r = 0.368, p = 0.003)
and Hgb (r = 0.368, p = 0.001), and negatively correlated
with platelet number (r = −0-450, p < 0.001). α correlated
with platelet number (r = 0.475, p < 0.001) and had negative
correlations with APTT (r = −0354, p = 0.003) and
Hgb (r = −0.414, p < 0.001). R was only correlated with
APTT (r = 0.339, p < 0.001).
Discussion
We observed that the normal variability in non-bleeding,
non-transfused ICU patients included in this study in-
cluded TEG® values for MA and G higher than reference
values. Other coagulation tests were also abnormal with
D-Dimer, fibrinogen, APTT values higher than reference
values and ATIII lower than reference values.
We observed that approximately 73% of the patients
had a TEG® profile suggesting hypercoagulability reflected
by a high MA value [6,12]. None of the patients had a MA
value corresponding to hypocoagulability. This finding
differs from a study by Ostrowski et al. who observed that
30% of septic ICU patients were hypocoagulable, 22%
were hypercoagulable and 48% were normocoagulable [6].
The authors suggested that these findings reflected the
severity of sepsis and that TEG® values were independently
associated with 28-day mortality [6]. Massion et al. alsoreported the presence of a hypocoagulable state caused by
hyperfibrinolysis measured with thromboelastometry
and standard coagulation tests in patients diagnosed
with septic shock [13]. The differences between these
studies and our results are not exclusively explained by
different case loads, septic patients versus a mixed ICU
population, because many patients also in our cohort
were septic.
We did not observe any of the correlations of TEG®
values with age, gender or time from sampling to ana-
lysis that are described in other studies in other patient
populations [14-16]. This lack of associations may sug-
gest that the many clinical factors influencing coagula-
tion in ICU patients minimize the relative contribution
to variability from some of the factors relevant in a
healthy population [14-16]. In our population the me-
dian hemoglobin serum concentration was lower than
reference values and hemoglobin serum concentration
correlated negatively with MA. This is in accordance
with other studies, where low hemoglobin values are
associated with high MA and R values in vitro [17,18].
Ostrowski et al. showed that fibrinogen but not platelets
contributed to TEG® clot strength in hypocoagulable and
hypercoagulable patients, whereas both platelets and
fibrinogen contributed independently to TEG® clot strength
in normocoagulable patients [6]. In our study we observed
that both fibrinogen and platelet count were associated
with MA.
Critically ill patients have many similar physiological
disturbances, often elicited by a non-specific systemic
inflammatory response syndrome, regardless of the
underlying disease. In this study, we selected an ICU
population without on-going bleeding and with no spe-
cific factors related to a haematological disease or thera-
peutic anticoagulation therapy. Furthermore, different
from previous studies, we did not restrict the analyses to
patients with sepsis. Thus, the TEG® values in our study
population might be representative for ICU patients in
general. ICU patient case-mix may be different in other
ICU cohorts, in the ICU cohort in this study the severity
of disease was high as illustrated by the median SAPS II
score of 38. We observed that the majority of the study
population had MA and G values higher than reference
values, which would suggest hypercoagulability. Other
TEG® parameters were mostly within references values,
while traditional coagulation measures showed, as ex-
pected, high values of D-dimer and fibrinogen and low
values of AT-III. This finding has implications for the in-
terpretation of TEG® findings in bleeding ICU patients
in order to differentiate between findings expected to be
associated with the cause of bleeding and findings that
simply can be a part of the inflammatory process. Thus,
TEG® findings may be interpreted different in ICU pa-
tient than in patients with acute bleeding due to the
Table 1 Demographic data and clinical chemistry results
N* Median Interquartile range
Age 61 47-69
Gender (male) 50 (61%)
Diagnostic category Trauma 11 (13.4%)
Circulation 7 (8.5%)
Respiration 19 (23.2%)
Post-operative 9 (11.0%)
Infection/sepsis 12 (14.6%)
Gastrointestinal 5 (6.1%)
CNS non-trauma 11 (13.4%)
Others 8 (9.8%)
SAPS II 38 29-49
Total SOFA score 6 4-8
Number of organ failures 0 18
1 29
2 24
3 10
≥4 0
Medications Beta blockers 16 (19.5%)
Calcium blockers 6 (7.3%)
Nitro-preperations 1 (1.2%)
Diuretics 46 (56.1%)
Enoxaprin low dose 60 (73.2%)
ASA low dose 4 (4.9%)
Vasoactive substances 60 (73.2%)
Insulin 49 (59.8%)
Propofol 41 (50.0%)
Benzodiazepines 49 (59.8%)
Opioids 71 (86.6%)
Antibiotics 67 (81.7%)
Clinical chemistry** Hemoglobin (g/dL) 9.9 9.2-11.1
White blood cell count (109/L) 12.8 9.7-16.5
Creatinine (μmol/L) 63 44-108
Bilirubin (μmol/L) 6 4-12
Sodium (mmol/L) 138 135-141
Potassium (mmol/L) 3.98 3.72-4.23
Calcium ionized (mmol/L) 1.14 1.10-1.18
Magnesium (mmol/L) 0.81 0.73-0.88
Phosphate (mmol/L) 0.96 0.75-1.08
Albumin (g/L) 24 20-27
CRP (mg/L) 121 67-201
*N = number of patients (percent of study population). CNS = central nervous system. SAPS II = Simplified Acute Physiology Score II. SOFA = Sequential Organ
Failure Assessment score. ASA = acetylsalicylic acid. WBC = white blood count. CRP = C reactive protein. **Clinical chemistry reference values: Hb: 11.7 - 15.3
(female) and 13.4 - 17.0 (male). WBC: 3.7 – 10 . Creatinine: 45–90 (female) and 60 – 105 (male). Bilirubin (total): 5 – 25. Sodium: 137 – 145. Potassium: 3.6 – 4.6.
Calcium ionized: 1.18 – 1.32. Magnesium: 0.71 – 0.94. Phosphate: 0.85 – 1.85 (female) and 0.75 - 1.35 (male). Albumin: 34 – 45. CRP: <5.
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Table 2 Results of TEG® and other coagulation tests
Number Results Number of tests in relation to normal values*.**
Above Within Below
TEG®
R (min) 82 5.75 (4.78-6.83) 12 70 0
K (min) 82 1.45 (1.20-1.90) 5 71 6
α (deg) 82 69.8 (63.9-73.3) 4 71 7
MA (mm) 82 73.4 (68.3-78.2) 60 22 0
G (dyn/cm2) 82 13.8 (10.8-18.0) 60 22 0
Other coagulation results
Platelets (109/L) 82 216 (163–336) 14 52 16
INR 80 1.2 (1.1-1.3) 25 55 0
D-dimer (mg/L) 69 4.0 (2.5-8.6) 67 2
Fibrinogen (g/L) 71 6.5 (4.7-7.6) 61 10 0
AT III (%) 65 82.0 (68.0-100.5) 3 23 39
APTT (sec) 70 38.0 (34.0-43.0) 13 56 1
All results given In median (interquartile range) *Manufacturers reference values. TEG® 5000: R: 2–8. K: 1–3. α: 55–78. MA: 51–69. G: 4.6-10.9.
**Clinical chemistry reference values: platelets: 145–390. International normalised ratio (INR): 0.9-1.2. D-dimer < 0.5. Fibrinogen: 2.0-4.0. antithrombin III (AT-III):
89–118. activated partial thromboplastin time (APTT): 30–44.
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failure.
We recognize some limitations in this study. First,
we have no data regarding the patients that were not
included. However, we do not know of any system-
atic bias in the inclusions. Second, the results may
be different in ICU populations with a different case-
mix. Thirdly, only one sample was obtained from
each patient, thus inter-test-variability could not be
analysed. Finally, as this is a study performed in theTable 3 Correlations between TEG®-values. coagulation tests
R K
Platelets Correlation −0.180 −
Sig. (2-tailed) 0.106 <
INR Correlation 0.0.80 0
Sig. (2-tailed) 0.478 0
D-dimer Correlation 0.0.22 −
Sig. (2-tailed) 0.858 0
Fibrinogen Correlation 0.004 −
Sig. (2-tailed) 0.977 0
AT-III Correlation 0.027 −
Sig. (2-tailed) 0.832 0
APTT Correlation 0.339 0
Sig. (2-tailed) 0.001 0
Hemoglobin Correlation 0.125 0
Sig. (2-tailed) 0.267 0
All correlations are Spearmans correlations. Bold text represents correlations with aICU all samples are collected from an arterial line,
which may be different from analyses performed in
venous blood.
Conclusion
ICU patients without bleeding or known factors that in-
fluence coagulation have often high TEG® values of MA
and G suggesting hypercoagulability. This finding should
be considered when interpreting TEG® observations ob-
tained in ICU patients.and Hb
α MA G
0.450 0.475 0.680 0.882
0.001 <0.001 <0.001 <0.001
.207 −0.200 −0.168 −0.166
066 0.076 0.136 0.140
0.033 0.068 0.246 0.244
785 0.579 0.042 0.0.44
0.160 0205 0.619 0.617
.183 0.086 <0.001 <0.001
0.241 0.246 0.279 0.280
.054 0.0.48 0.024 0.024
.348 −0.354 −0.075 −0.076
.003 0.003 0.538 0.531
.368 −0.414 −0.379 −0.377
.001 0 < .001 <0.001 0.001
p-value < 0.01.
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 Hypercoagulability showed by high MA and G
values at tromboelastography (TEG®) is frequent
in an unselected ICU population with no ongoing
bleeding.
 Other tromboelastography (TEG®) values than
MA and G are usually within normal values in an
unselected ICU population with no ongoing
bleeding.
Abbreviations
Α: Angle; APTT: Activated partial thromboplastin time; ATIII: Anti-thrombin III;
CaCl2: Calciumcloride; CRP: C-reactive protein; Hgb: Hemoglobin; ICU: Intensive
care unit; INR: International normalized ratio; K: k-time; MA: Maximum
amplitude; PT: Prothrombin time; R: Reaction time; ROTEM: Rotational
thomboelastometry; SAPS II: Simplified acute physiology score II;
SOFA: Sequential organ failure assessment; TEG®: Thromboelastography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JHH performed the data management and analyzed the data, participated in
the design of the study and drafted the manuscript. SWH performed the
data management and analyzed the data, participated in the design of the
study and drafted the manuscript. AE performed the laboratory analyses,
analyzed the data, participated in the design of the study and drafted the
manuscript. PK conceived the study, obtained the samples, analyzed the
data, participated in the design of the study and drafted the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We acknowledge the assistance from physicians and nurses at the Intensive
Care Unit and the bioengineers at the Dept. of Immunology and Transfusion
Medicine. St. Olav University Hospital. Trondheim. Norway.
Author details
1Faculty of Medicine, Norwegian University of Science and Technology,
Trondheim, Norway. 2Department of Immunology and Transfusion Medicine,
St. Olav University Hospital, Trondheim, Norway. 3Department of
Anesthesiology and Intensive Care Medicine, St. Olav University Hospital,
Trondheim, Norway. 4Department of Circulation and Medical Imaging,
Faculty of Medicine, Norwegian University of Science and Technology,
Trondheim, Norway. 5Department of Intensive Care Medicine, St. Olav
University Hospital, P.O. box 3250 Sluppen, N-7006 Trondheim, Norway.
Received: 14 June 2014 Accepted: 21 February 2015
References
1. Borgel D, Bornstain C, Reitsma PH, Lerolle N, Gandrille S, Dali-Ali F, et al. A
comparative study of the protein C pathway in septic and nonseptic
patients with organ failure. Am J Respir Crit Care Med. 2007;176:878–85.
2. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab
Haematol. 2005;27:81–90.
3. Afshari A, Wikkelso A, Brok J, Moller AM, Wetterslev J. Thrombelastography
(TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus
usual care in patients with massive transfusion. Cochrane Database Syst Rev.
2011, Issue 3. Art. No.: CD007871. doi:10.1002/14651858.CD007871.pub2.
4. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F,
Ergin MA. Thromboelastography-guided transfusion algorithm reduces
transfusions in complex cardiac surgery. Anesth Analg. 1999;88:312–9.
5. Harnett MJ, Bhavani-Shankar K, Datta S, Tsen LC. In vitro fertilization-induced
alterations in coagulation and fibrinolysis as measured by thromboelastography.
Anesth Analg. 2002;95:1063–6.
6. Ostrowski SR, Windelov NA, Ibsen M, Haase N, Perner A, Johansson PI.
Consecutive thrombelastography clot strength profiles in patients withsevere sepsis and their association with 28-day mortality: a prospective
study. J Crit Care. 2013;28:317. e311-311.
7. Scarpelini S, Rhind SG, Nascimento B, Tien H, Shek PN, Peng HT, et al.
Normal range values for thromboelastography in healthy adult volunteers.
Braz J Med Biol Res. 2009;42:1210–7.
8. Muller MC, Meijers JC, Vroom MB, Juffermans NP. Utility of
thromboelastography and/or thromboelastometry in adults with sepsis: a
systematic review. Crit Care. 2014;18:R30.
9. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology
Score (SAPS II) based on a European/North American multicenter study.
JAMA. 1993;270:2957–63.
10. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al.
Use of the SOFA score to assess the incidence of organ dysfunction/failure
in intensive care units: results of a multicenter. prospective study. Working
group on “sepsis-related problems” of the European Society of Intensive
Care Medicine. Crit Care Med. 1998;26:1793–800.
11. TEG 5000 User’s Manual 1999–2007. Haemoscope Corporation. Niles. IL. USA.
12. Ostrowski SR, Sorensen AM, Larsen CF, Johansson PI. Thrombelastography
and biomarker profiles in acute coagulopathy of trauma: a prospective
study. Scand J Trauma Resusc Emerg Med. 2011;19:64.
13. Massion PB, Peters P, Ledoux D, Zimermann V, Canivet JL, Massion PP, et al.
Persistent hypocoagulability in patients with septic shock predicts greater
hospital mortality: impact of impaired thrombin generation. Intensive Care
Med. 2012;38:1326–35.
14. Ng KF. Changes in thrombelastograph variables associated with aging.
Anesth Analg. 2004;99:449–54.
15. White H, Zollinger C, Jones M, Bird R. Can Thromboelastography performed
on kaolin-activated citrated samples from critically ill patients provide stable
and consistent parameters? Int J Lab Hematol. 2010;32:167–73.
16. Gorton HJ, Warren ER, Simpson NA, Lyons GR, Columb MO.
Thromboelastography identifies sex-related differences in coagulation.
Anesth Analg. 2000;91:1279–81.
17. Roeloffzen WW, Kluin-Nelemans HC, Bosman L, de Wolf JT. Effects of red
blood cells on hemostasis. Transfusion. 2010;50:1536–44.
18. Bochsen L, Johansson PI, Kristensen AT, Daugaard G, Ostrowski SR. The
influence of platelets. plasma and red blood cells on functional haemostatic
assays. Blood Coagul Fibrinolysis. 2011;22:167–75.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
